Drug Type Synthetic peptide |
Synonyms JSM 6427 |
Target |
Action antagonists |
Mechanism α5β1 antagonists(Integrin alpha-5/beta-1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glycogen Storage Disease Type II | Phase 1 | United States | 01 Sep 2007 | |
| Wet age-related macular degeneration | Phase 1 | United States | 01 Sep 2007 | |
| Vitreoretinopathy, Proliferative | Preclinical | Germany | 01 May 2007 | |
| Retinopathy of Prematurity | Preclinical | Germany | 01 May 2006 |
Phase 1 | - | vghntsvivl(hbjrfptalf) = xystesghuh ygsfqmqgaj (eoabydhsfb ) | - | 01 Apr 2009 | |||
Phase 1 | - | pgqgqocrxx(aswdkifpax) = bqffkcvsfh otjcxiehfh (ywbfndecua ) View more | Positive | 01 May 2008 |






